Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of STC007 injection for chronic kidney disease-associated pruritus in adults receiving hemodialysis
CTR20250717Phase 2Active
- Sponsor
- Chengdu Nuoshengtai Biotechnology
- Start
- Apr 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of bupivacaine liposome in chronic kidney disease (CKD), sponsored by Chengdu Nuoshengtai Biotechnology. Started Apr 2026; status: active.
02
Drugs
bupivacaine liposome
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20250717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250717.